|
Sun Pharma Q1 Results FY26: Sun Pharmaceutical Industries reported a 20% fall in Q1 consolidated net profit, reaching Rs 2,278 crore. Despite this dip, revenue from operations increased by 10% to Rs 13,786 crore. Strong performance in the India market and growth in global innovative medicines sales, including the U.S. launch of LEQSELVI, contributed to the company's overall progress.
Category:
News and Media
Vikas Khemani of Carnelian Asset Management suggests that while U.S. tariffs may cause short-term earnings uncertainty for Indian exporters, a major structural risk to the overall market is unlikely. The markets have largely priced in the potential impact of a 25% tariff, and India's strong domestic consumption and infrastructure development provide a buffer.
Category:
News and Media
The BBC investigates the challenges of closing high street shops selling illegal tobacco
Category:
News and Media
All news |
||||||||||||||||||
|